Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours

C Horbinski, T Berger, RJ Packer, PY Wen - Nature Reviews Neurology, 2022 - nature.com
A new edition of the WHO classification of tumours of the CNS was published in 2021.
Although the previous edition of this classification was published just 5 years earlier, in …

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

M Weller, M van den Bent, M Preusser… - Nature reviews Clinical …, 2021 - nature.com
In response to major changes in diagnostic algorithms and the publication of mature results
from various large clinical trials, the European Association of Neuro-Oncology (EANO) …

A prognostic neural epigenetic signature in high-grade glioma

R Drexler, R Khatri, T Sauvigny, M Mohme, CL Maire… - Nature Medicine, 2024 - nature.com
Neural–tumor interactions drive glioma growth as evidenced in preclinical models, but
clinical validation is limited. We present an epigenetically defined neural signature of …

Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness

Y Li, TSM Lih, SM Dhanasekaran, R Mannan, L Chen… - Cancer cell, 2023 - cell.com
Clear cell renal cell carcinomas (ccRCCs) represent∼ 75% of RCC cases and account for
most RCC-associated deaths. Inter-and intratumoral heterogeneity (ITH) results in varying …

Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology

D Sturm, D Capper, F Andreiuolo, M Gessi… - Nature medicine, 2023 - nature.com
The large diversity of central nervous system (CNS) tumor types in children and adolescents
results in disparate patient outcomes and renders accurate diagnosis challenging. In this …

[HTML][HTML] Prognostic and predictive biomarkers in gliomas

P Śledzińska, MG Bebyn, J Furtak… - International journal of …, 2021 - mdpi.com
Gliomas are the most common central nervous system tumors. New technologies, including
genetic research and advanced statistical methods, revolutionize the therapeutic approach …

[HTML][HTML] Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways

S Venneti, AR Kawakibi, S Ji, SM Waszak… - Cancer …, 2023 - aacrjournals.org
Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven effective
therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism …

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future …

PY Wen, M Weller, EQ Lee, BM Alexander… - Neuro …, 2020 - academic.oup.com
Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading

DN Louis, P Wesseling, K Aldape, DJ Brat, D Capper… - 2020 - Wiley Online Library
Abstract cIMPACT‐NOW (the Consortium to Inform Molecular and Practical Approaches to
CNS Tumor Taxonomy) was established to evaluate and make practical recommendations …

Cancer epigenetics in clinical practice

V Davalos, M Esteller - CA: a cancer journal for clinicians, 2023 - Wiley Online Library
Cancer development is driven by the accumulation of alterations affecting the structure and
function of the genome. Whereas genetic changes disrupt the DNA sequence, epigenetic …